Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 685 across all filing types
Latest filing 2022-12-14 Regulatory Filings
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Anti-Infective Research Unit est. at Murdoch Children's 4 pages 335.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement detailing the establishment of a new Anti-Infective Research Unit at Murdoch Children’s Research Institute by Recce Pharmaceuticals. It focuses on research collaboration, pre-clinical program updates, and pipeline information. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The content is a corporate announcement about a research collaboration and business development, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the collaboration and research unit establishment. Therefore, the document fits best under the category of a general regulatory announcement or corporate update, which corresponds to Regulatory Filings (RNS).
2022-12-14 English
Approval to Start Phase I/II Diabetic Foot Ulcer Study 4 pages 332.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Recce Pharmaceuticals about receiving ethics approval to start a Phase I/II clinical trial for a diabetic foot ulcer study. It discusses the clinical trial's purpose, patient enrollment, and study details but does not contain financial data, earnings, or regulatory filings. It is a corporate announcement about a clinical trial milestone rather than a financial report or regulatory filing. Therefore, it fits best under the category of a general regulatory announcement or corporate update that does not fit other specific categories, which corresponds to Regulatory Filings (RNS). The document length is about 5978 characters, which is sufficient for a detailed announcement but does not contain financial statements or detailed report data.
2022-12-08 English
Pause in Trading 1 page 108.7KB
Regulatory Filings Classification · 95% confidence The document is a short market release announcing a temporary pause in trading of the company's securities. It is a brief regulatory announcement without financial data, report content, or detailed analysis. It does not fit into categories like financial reports, management information, or capital updates. It is a regulatory announcement related to trading status, best classified under Regulatory Filings (RNS).
2022-12-06 English
Trading Halt 2 pages 660.1KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Recce Pharmaceuticals Ltd regarding a trading halt requested under ASX Listing Rule 17.1. It states that the trading halt is pending the release of an announcement related to Human Research Ethics Committee approval for a Phase II study. The document is short (1952 characters) and does not contain any financial data, report content, or detailed analysis. It is an announcement about a trading halt, not a financial report or detailed disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and compliance documents that do not fit other specific categories.
2022-12-06 English
Notification regarding unquoted securities - RCE 6 pages 28.4KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from RECCE PHARMACEUTICALS LTD dated November 15, 2022, regarding the issue of unquoted securities under an employee incentive scheme. It details the number and type of securities issued, including options and performance shares, and mentions that some securities were issued to a director as approved by shareholders at the AGM. The document includes specifics about the securities, issue dates, and compliance with ASX listing rules. There is no financial performance data, audit information, or management discussion. The content is focused on the issuance of securities, which aligns with announcements about share issues or capital changes. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length (8063 characters) and detailed issuance information support this classification with high confidence.
2022-11-14 English
Change of Director's Interest Notice - A McKeough 3 pages 310.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of securities held before and after the change, nature of the change, and other related information. This type of document is a formal notification of personal share transactions by a company director, commonly known as a director's dealing report. It does not contain financial statements, management discussion, or other report content. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a certification but a full notice of director's interest change.
2022-11-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.